0 10 Expression expression NN 11 13 of of IN 14 26 IkappaBalpha IkappaBalpha NNP 27 29 in in IN 30 33 the the DT 34 41 nucleus nucleus NN 42 44 of of IN 45 50 human human JJ 51 61 peripheral peripheral JJ 62 67 blood blood NN 68 69 T t NN 70 81 lymphocytes lymphocyte NNS 81 82 . . . 84 93 According accord VBG 94 96 to to TO 97 104 current current JJ 105 111 models model NNS 112 115 the the DT 116 126 inhibitory inhibitory JJ 127 135 capacity capacity NN 136 138 of of IN 139 155 I(kappa)B(alpha) I(kappa)B(alpha) NNP 156 161 would would MD 162 164 be be VB 165 173 mediated mediate VBN 174 181 through through IN 182 185 the the DT 186 195 retention retention NN 196 198 of of IN 199 212 Rel/NF-kappaB Rel/NF-kappaB NNP 213 221 proteins protein NNS 222 224 in in IN 225 228 the the DT 229 236 cytosol cytosol NN 236 237 . . . 238 245 However however RB 245 246 , , , 247 263 I(kappa)B(alpha) I(kappa)B(alpha) NNP 264 267 has have VBZ 268 272 also also RB 273 277 been be VBN 278 286 detected detect VBN 287 289 in in IN 290 293 the the DT 294 301 nucleus nucleus NN 302 304 of of IN 305 309 cell cell NN 310 315 lines line NNS 316 319 and and CC 320 324 when when WRB 325 338 overexpressed overexpresse VBN 339 341 by by IN 342 351 transient transient JJ 352 364 transfection transfection NN 364 365 . . . 366 368 To to TO 369 373 gain gain VB 374 380 better good JJR 381 388 insight insight NN 389 393 into into IN 394 397 the the DT 398 407 potential potential JJ 408 412 role role NN 413 415 of of IN 416 423 nuclear nuclear JJ 424 440 I(kappa)B(alpha) i(kappa)b(alpha) NN 441 443 in in IN 444 445 a a DT 446 459 physiological physiological JJ 460 467 context context NN 468 470 we we PRP 471 475 have have VBP 476 484 analysed analyse VBN 485 488 its its PRP$ 489 497 presence presence NN 498 500 in in IN 501 504 the the DT 505 512 nucleus nucleus NN 513 515 of of IN 516 521 human human JJ 522 532 peripheral peripheral JJ 533 538 blood blood NN 539 540 T t NN 541 552 lymphocytes lymphocyte NNS 553 554 ( ( ( 554 557 PBL PBL NNP 557 558 ) ) ) 558 559 . . . 560 562 We we PRP 563 574 demonstrate demonstrate VBP 575 578 the the DT 579 586 nuclear nuclear JJ 587 599 localization localization NN 600 602 of of IN 603 619 I(kappa)B(alpha) I(kappa)B(alpha) NNP 620 622 in in IN 623 626 PBL PBL NNP 627 629 by by IN 630 639 different different JJ 640 650 techniques technique NNS 650 651 : : : 652 659 Western western JJ 660 664 blot blot NN 664 665 , , , 666 674 indirect indirect JJ 675 693 immunofluorescence immunofluorescence NN 694 697 and and CC 698 706 electron electron NN 707 717 microscopy microscopy NN 717 718 . . . 719 722 Low low JJ 723 729 levels level NNS 730 732 of of IN 733 740 nuclear nuclear JJ 741 757 I(kappa)B(alpha) i(kappa)b(alpha) NN 758 762 were be VBD 763 771 detected detect VBN 772 774 in in IN 775 782 resting rest VBG 783 788 cells cell NNS 789 796 whereas whereas IN 797 798 a a DT 799 813 superinduction superinduction NN 814 817 was be VBD 818 826 obtained obtain VBN 827 832 after after IN 833 836 PMA PMA NNP 837 847 activation activation NN 847 848 . . . 849 852 The the DT 853 860 nuclear nuclear JJ 861 865 pool pool NN 866 868 of of IN 869 885 I(kappa)B(alpha) I(kappa)B(alpha) NNP 886 892 showed show VBD 893 894 a a DT 895 901 higher high JJR 902 911 stability stability NN 912 916 than than IN 917 926 cytosolic cytosolic JJ 927 943 I(kappa)B(alpha) i(kappa)b(alpha) NN 944 947 and and CC 948 951 was be VBD 952 961 partially partially RB 962 973 independent independent JJ 974 976 of of IN 977 980 the the DT 981 992 resynthesis resynthesis NN 993 995 of of IN 996 999 the the DT 1000 1007 protein protein NN 1007 1008 . . . 1009 1021 Unexpectedly unexpectedly RB 1021 1022 , , , 1023 1026 the the DT 1027 1035 presence presence NN 1036 1038 of of IN 1039 1046 nuclear nuclear JJ 1047 1063 I(kappa)B(alpha) i(kappa)b(alpha) NN 1064 1067 did do VBD 1068 1071 not not RB 1072 1079 inhibit inhibit VB 1080 1089 NF-kappaB NF-kappaB NNP 1090 1097 binding binding NN 1098 1100 to to TO 1101 1104 DNA DNA NNP 1105 1108 and and CC 1109 1113 this this DT 1114 1124 phenomenon phenomenon NN 1125 1128 was be VBD 1129 1132 not not RB 1133 1136 due due JJ 1137 1139 to to TO 1140 1143 the the DT 1144 1152 presence presence NN 1153 1155 of of IN 1156 1167 IkappaBbeta IkappaBbeta NNP 1168 1170 at at IN 1171 1174 the the DT 1175 1182 nuclear nuclear JJ 1183 1188 level level NN 1188 1189 . . . 1190 1209 Immunoprecipitation Immunoprecipitation NNP 1210 1221 experiments experiment NNS 1222 1228 failed fail VBD 1229 1231 to to TO 1232 1243 demonstrate demonstrate VB 1244 1246 an an DT 1247 1258 association association NN 1259 1266 between between IN 1267 1274 nuclear nuclear JJ 1275 1291 I(kappa)B(alpha) i(kappa)b(alpha) NN 1292 1295 and and CC 1296 1305 NF-kappaB nf-kappab NN 1306 1314 proteins protein NNS 1314 1315 . . . 1316 1319 Our our PRP$ 1320 1327 results result NNS 1328 1339 demonstrate demonstrate VBP 1340 1344 that that IN 1345 1347 in in IN 1348 1355 resting rest VBG 1356 1359 and and CC 1360 1373 PMA-activated pma-activated JJ 1374 1379 human human JJ 1380 1383 PBL PBL NNP 1383 1384 , , , 1385 1401 I(kappa)B(alpha) I(kappa)B(alpha) NNP 1402 1404 is be VBZ 1405 1412 present present JJ 1413 1415 in in IN 1416 1419 the the DT 1420 1427 nucleus nucleus NN 1428 1430 in in IN 1431 1433 an an DT 1434 1444 apparently apparently RB 1445 1453 inactive inactive JJ 1454 1458 form form NN 1459 1465 unable unable JJ 1466 1468 to to TO 1469 1476 disrupt disrupt VB 1477 1486 NF-kappaB NF-kappaB NNP 1487 1494 binding binding NN 1495 1499 from from IN 1500 1503 DNA DNA NNP 1503 1504 . . .